Nanoparticles for Ultrasound-Guided Imaging of Cell Implantation

James Hartanto and Jesse V. Jokerst

1 Stem Cell Therapy

Stem cell therapy is established for many regenerative medicine applications and has shown remarkable impact in treating disease. Stem cell therapy is part of a larger component of medicine known as regenerative medicine. While the exact definition of regenerative medicine continues to evolve [1], one definition is that it creates living, functional tissues to repair or replace tissue or organ function lost due to age, disease, damage, or congenital defects [2, 3]. Cell-based therapies are particularly attractive because cells are the basic building block of tissue and can create functional tissue when added in sufficient numbers. Cell-based therapy often delivers cells directly to the site of disease, which can provide much greater efficacy than therapeutics that are delivered intravenously. Finally, stem cells can be directed into diverse lineages that are in turn tailored to specific diseases.

Cell-based therapy has been used for many applications in regenerative medicine. Examples include increasing the volume of blood being pumped by the left ventricle after myocardial infarction [4, 5], increasing the strength of muscles and the size of muscles in muscular dystrophy patients [6, 7], and decreasing joint pain in arthritis [8]. Other groups have shown that cells and tissues can be grown on support scaffolds to create entire new bulk pieces of tissue including the larynx and cornea [9]. Stem cell therapy has been described with many diverse starting materials including mesenchymal stem cells, embryonic stem cells, induced pluripotent stem cells, and adipose-derived stem cells [10]. Before, during, and after delivery of cells, researchers, physicians, and patients may have many questions about the fate of the cells including the following: (1) Are the cells alive? (2) What proteins are the

J. Hartanto • J.V. Jokerst (✉)
Department of NanoEngineering, University of California,
9500 Gilman Drive, San Diego, La Jolla, CA 92093-0448, USA
e-mail: jjokerst@ucsd.edu

cells expressing? (3) Where are the cells located? (4) How are the cells interacting with the surrounding tissue? (5) How has the cells' biochemical signature changed after delivery?

In vivo imaging is ideally suited to answer these questions because it can be done serially in real time, is noninvasive, and can often be carried out with high temporal and spatial resolution. The repeat nature of imaging is particularly important in stem cell therapy because the repair is a dynamic process and it is important to frequently assess the status of the therapy. Alternative techniques that do not use imaging such as biopsy are more difficult to do repeatedly over time. While no single imaging approach can yet answer all of the above questions, significant advances have been made—particularly in understanding the cell number, viability, and location.

1.1 General Approaches for Imaging in Stem Cell Therapy

There are two main approaches to stem cell imaging—direct and indirect (Fig. 1) [11]. Indirect imaging involves adding a reporter gene to the stem cell to produce a receptor, enzyme, or fluorescent/bioluminescent protein to create contrast and

Fig. 1 Approaches to labeling stem cells. Panel **a** shows direct imaging in which an exogenous material is placed inside a cell. The cells are then purified and implanted into an animal. Over time, the amount of contrast agent per cells decreases as the cells divide. In contrast, in indirect imaging (**b**), a reporter gene is placed inside the cell. These reporter genes either produce a label or affect an injected substrate that increases contrast in the cells of interest. Because the reporter gene is an inherent part of the cells' biology, this reporter is passed to all progeny with no dilution effects. However, a substrate has to be repeatedly injected for each imaging event. Reproduced with permission from Ref. [12]

report the cells' location, number, etc. These gene products can produce signal directly such as green fluorescent protein in optical imaging or can produce a secondary reaction with an exogenous label introduced at the time of imaging. For example, the herpes simplex virus type 1 thymidine kinase (HSV1-tk) can selectively phosphorylate substrates that are tagged for imaging with positron emission tomography (PET). This phosphorylation causes selective probe accumulation only in cells that carry the reporter gene, and thus stem cells can be imaged because of the increased levels of this reporter. The luciferase/luciferin reaction in bioluminescent imaging is another example of the need to inject a substrate. The advantages of indirect imaging are that the daughter cells normally receive a copy of the reporter gene and thus the signal is "on" only when the cell is viable. The disadvantage is that this requires reprogramming of the cells' genome—something that is very difficult to clinically translate. Thus, the majority of regenerative medicine work reported in humans has used direct labels.

Cell-Based Therapy in History

Some of the first reported instances of cell-based therapy were done to counteract the aging process. The French physician Charles-Édouard Brown-Séquard was known to inject pulverized animal testicles into human subjects. Unfortunately, little long-term impact was ever noted. In 1931 Dr. Paul Niehans treated an athymic patient with cells from a bovine thyroid. Although these therapies were also failures because of immune differences between species, his work was visionary, and he described "a method of treating the whole organism on a biological basis, capable of revitalizing the human organism with trillions of cells by bringing to it those embryonic or young cells which it needs." During the 1950s and 1960s bone marrow transplantation became increasingly sophisticated and matured from grafts between identical twins to grafts between siblings as the knowledge about graft-versus-host disease increased. The first transplant between unrelated persons was in 1973, which led in time to the transplantation of entire organs. The current state of the art is *stem cell* therapy, which uses cells capable of diverse lineages to repair tissue.

In direct labeling, cells are tagged with small molecules including radioisotopes, fluorophores, and nanoparticles. These can be added during expansion in tissue culture or immediately before injection. Transfection reagents may be used to increase the efficiency of label uptake. The labels can either be on the cell surface or inside the cell. One advantage of intracellular labeling is that there is a reduced chance of the label becoming disassociated from the cell and contributing to artificially high background or erroneous signal.

Direct labeling is attractive because it is simple and straightforward to control the dose of contrast with short processing times [12]. The major limitations are dilution of the concentration of contrast with successive cell division—that is, each

daughter cell only has 50 % of the amount of label as the parent cell (Fig. 1). In addition, these labels are usually "always on." They will report the presence of cells even if the cells are dead. These direct labels can also be taken up by macrophages after cells have died, which can also contribute to inaccurate cell counts.

Common examples include lipophilic fluorophores for optical imaging and (carboxy)dextran-coated super paramagnetic iron oxide (SPIO) nanoparticles such as Feridex® and Resovist® for MRI [13]. While cell loading is traditionally done ex vivo, one interesting report showed that i.v.-injected SPIO nanoparticles can accumulate in the bone marrow and label stem cells in the bone marrow in vivo through the reticuloendothelial system [14]. Fluorescent dyes have value in small animal models, but humans have too much optical scatter for direct optical labels. Radionuclides include fluorodeoxyglucose (^{18}F-FDG) in PET and ^{111}In oxine for single-photon emission computed tomography (SPECT), but one limitation of nuclear imaging methods is that the radioisotope decays over time making it difficult to perform longitudinal scans using radionuclides. More detailed descriptions of direct labels can be found elsewhere [15].

One area of imaging that has been significantly overlooked for cell tracking is ultrasound, which is somewhat surprising because ultrasound offers good temporal resolution and is widely available—features congruous with the needs of the stem cell imager. The balance of this chapter focuses on the use of ultrasound in stem cell tracking and describes the basis of contrast in ultrasound imaging as well as the types of ultrasound labels, examples of direct and indirect labeling with ultrasound, and some perspectives on future growth in the field.

2 The Rationale for Ultrasound Imaging

Ultrasound imaging offers many advantages that are useful to studying stem cell therapy. First, ultrasound is very accessible and affordable. It is by far the most common piece of imaging equipment worldwide from small rural clinics to major research university hospitals. Second, ultrasound offers spatial resolution advantages (~50 μm) that are useful to identify subtle differences in treated tissue. Third, ultrasound offers excellent temporal resolution (up to 1000 frames per second)—this is critical for instantaneous knowledge of the cell location and the cell number. Fourth, ultrasound data can be quantitative, which is critical for identifying not only the presence of the cells, but also their number. Fifth, ultrasound offers a broad portfolio of complementary imaging sequences that can be used to enhance the cell data. That is, the ultrasound can collect imaging data about the surrounding anatomy and tissue behavior that complements the functional information from the cells. This includes motion mode (M-mode) imaging that studies repetitive motion such as the heart chamber [16], Doppler imaging which monitors the direction of movement [17], and various quantification schemes that can be used to estimate organ size or cardiac behavior including the left ventricle ejection fraction [18]. However, ultrasound images can also be very difficult to interpret due to the high

Fig. 2 Performance features of various imaging modalities. The temporal resolution (time between images) and spatial resolution (distance between points that can be distinguished) are plotted for different imaging modalities. Ultrasound offers good temporal and spatial resolution


background noise and/or complicated acoustic properties of different tissues. This is especially problematic in stem cell imaging—thus, it is critical to use either a direct or an indirect imaging technique to increase the cell-specific contrast.

The features of ultrasound and a comparison to other techniques used for stem cell tracking are shown in Fig. 2. Ultrasound is particularly powerful because of its high temporal resolution. This allows nearly instantaneous readout of the features of interest including the cell location and cell number. On the *y*-axis in Fig. 2, we plot the spatial resolution—how fine of an image can be created or the smallest distance between two objects that can be resolved. In ultrasound the spatial resolution is a function of the frequency used to create the images. At 70–100 MHz, the resolution can be as high as tens of micrometers, while at clinical frequencies (2–10 MHz), the spatial resolution is much lower—hundreds of microns to millimeters. As a trade-off, lower frequencies do offer better penetration through tissue—clinical frequencies can easily penetrate up to 25 cm into human beings depending on the tissue type, while higher preclinical frequencies (used in rodent models of human disease) are often limited to 2–3 cm of tissue. Importantly, the temporal resolution (frames per second) does not change as a function of frequency.

2.1 Ultrasound Mechanism and Types of Ultrasound

Ultrasound imaging in vivo is not entirely different than the approach used by bats to "see in the dark." Ultrasound imaging uses a tool called a transducer (Fig. 3a). The transducer is simply a tool that both emits and receives ultrasound pressure waves. As the emitted sound wave passes through tissue it is scattered and reflected (echoed) back to the transducer. The image is created by interpreting the backscattered sound and direction of sound as well as the speed of sound, the time of emission, the

Fig. 3 Ultrasound mechanism. The mechanism of contrast in ultrasound. Traditional B-mode imaging (**a**) uses backscattered pressure waves to generate contrast. In photoacoustic imaging (**b**), an incident light is absorbed by the target tissue. Once absorbed the target heats and swells creating pressure differences that can be detected acoustically

time of arrival back at the transducer, and the angle of return. The reconstructed image thus reports the distance to the object, the size of the object, and its density (or impedance mismatch with the surrounding tissue). Most ultrasound images are two dimensions, but 3D ultrasound is possible by moving the transducer over the surface to be imaged (like a panorama shot on a mobile phone camera). Ultrasound can also be done in Doppler mode in which changes in the sound wave's pitch and phase are used to gain even more information. This is analogous to the sound differences when a siren is moving towards you and away from you. This can be used to determine blood flow or study other movement events inside the body.

In addition to Doppler ultrasound, photoacoustic ultrasound is another important subtype of ultrasound imaging. In the photoacoustic effect ultrasound waves are created due to incident light pulses on the tissue (Fig. 3b). That is, regular ultrasound is "sound in—sound out," and photoacoustic imaging is "light in—sound out." Alexander Graham Bell originally described the photoacoustic effect, but it has not been until recent years that people have used it for imaging because the transducers have become more sensitive and lasers have been developed with very short pulse lengths.

The mechanism is based on optical absorption—when the light is absorbed by the target tissue, the target heats, and swells. This thermal expansion then generates pressure waves that can be detected acoustically. The fundamental advantage of photoacoustic imaging is that it combines the high temporal and spatial resolution of ultrasound with the good contrast and spectral nature of optical imaging. Photoacoustic imaging can use both exogenous absorbers such as hemoglobin, deoxyhemoglobin, and melanin or artificial contrast agents targeted to site of interest or a cell of interest.

A third type of ultrasound imaging is contrast-enhanced ultrasound. This uses an exogenous agent such as a perfluorocarbon microbubble to artificially increase the ultrasound signal at the site of interest. Contrast-enhanced ultrasound can move beyond the anatomical images that are created with traditional imaging (bone, muscle, etc.) to imaging protein expression levels or specific stem cell types. In the following section, we discuss some of the types of ultrasound contrast agents used as well as their applications in stem cell therapy. Because of the performance features of ultrasound it is somewhat surprising that there are relatively few reports of this technology in the literature. We will present these case studies in chronological order and highlight various examples of direct and indirect imaging via ultrasound.

2.2 Ultrasound Imaging of Cardiac Stem Cell Therapy

Heart disease is the most common cause of death in the developed world. Stem cell therapy has shown encouraging initial results in treating heart disease [4], and yet is plagued by poor long-term efficacy because of poor cell viability after implantation [5, 19]. This is attributed to two fundamental challenges—(1) ischemia and inflammation in the treated area [19], and (2) mis-injection or implant into highly fibrotic tissue [20, 21]. Because of these barriers, one example showed that fewer than 2 % of implanted dendritic cells remain viable after 4–8 weeks [21] with cells mis-injected in 50 % of patients [22]. Ultrasound is ideally suited to solve these challenges with poor delivery. Physicians already use ultrasound to image the catheter used for delivery of cells into the cardiac tissue, but the cells have a low impedance mismatch with the surrounding tissue and thus have low contrast.

Ultrasound is particularly attractive in cardiac stem cell therapy of the heart because it can be combined with the established use of echocardiography. Echocardiography is also known as a "cardiac echo" or just an "echo," and it is used in the diagnosis and prevention of disease. Output parameters from echocardiography include the size and the shape of the ventricles and the left ventricle ejection fraction, which allows physicians to see how the heart chambers work in synchrony. This can be complemented by Doppler imaging to understand blood flow rates and directions.

In 2005, Rodriguez-Porcel and coworkers showed that ultrasound has fundamental utility in stem cell therapy [20]. Whereas prior work up to this point had performed open chest injection into the cardiac muscle, this study used ultrasound guidance in the parasternal long-axis view to deliver cells with a 28-gauge catheter. The cells were stably transfected cardiomyoblasts (plasmid–cytomegalovirus–firefly luciferase), and the target site was the anterior cardiac wall. The advantage of this approach is that the surgery is much less invasive and the surgeon can see the location of the catheter in real time. These researchers performed this work in 11 rats and then confirmed cell delivery with the bioluminescence reporter embedded in the cells. The bioluminescent signal was positively correlated with the number of cells transplanted ($R^2 = 0.94$, $P = 0.03$).

One limitation of this work was the poor ultrasound signal from the cells. That is, the investigators could only know the location and number of the cells with downstream analysis via bioluminescence. Thus, in 2006 Bara and colleagues [23] used ultrasound not only to image the injection but also to image the cells (Fig. 4) [23]. Here, cells were labeled with a clinically approved formulation of iron oxide (CliniMACS). These materials are used for magnetic based cell separation and consisted of a 50 nm iron oxide core coated with a dextran shell that is finally annealed to a monoclonal antibody specific to the target of interest. The authors selected CD133 because it is a marker of hematopoietic stem cells. After purifying CD133+ stem cells from bone marrow aspirates, cell identify and purity were confirmed with CD34 flow cytometry.

These cells were delivered to swine models of human ischemia created via ligation/reperfusion [24]. The swine received either stem cells (5 million) or a sham injection of saline. Imaging used transesophageal echocardiography, which is a specialized type of ultrasound imaging that places a transducer in the throat of the subject to increase resolution versus ultrasound imaging via the chest wall. Figure 4 presents data including cells without any label (Fig. 4a), the ClinicMACS particles alone (Fig. 4b), as well as an animal before (Fig. 4c) and after treatment


Fig. 4 Direct imaging with magnetic particles. Swine hearts are imaged at various stages of stem cell therapy. In each image, the dark oval in the center is the left ventricle. Note the clear boundary between the interior and exterior of the heart wall in **c** (between *red* and *green arrows*). Panel **a** shows injection of unlabeled cells in the area highlighted with red circle. Little signal increase is seen. When the nanoparticle contrast agent alone is injected, hyperechoic regions are seen (**b**). Panels **c** and **d** are pre- (**c**) and post- (**d**) injection images of animals treated with five million nanoparticle-labeled stem cells. Reproduced with permission from Ref. [25]

with labeled cells (Fig. 4d). The hypoechoic (bright) areas in Fig. 4b, d correspond to the increased sound backscatter due to the particles. The authors showed that the labeled cells had more signal than unlabeled cells but had challenges with long-term cell tracking. They concluded that this technique was perhaps best suited for the delivery event and that a complementary technique might be superior for long-term tracking.

In 2013, Jokerst et al. extended this to multimodal imaging with MRI and ultrasound. In contrast to the magnetic nanoparticles used by Bara [23], this group used silica nanoparticles as ultrasound contrast agents [25, 26]. These have a key advantage in that the nanoparticles can be loaded *inside* the stem cells whereas the magnetic particles were on the cell *exterior*. This is important because contrast agents on the cell exterior can easily become detached in vivo and lead to erroneous signal. The silica nanoparticles are also triple-modality agents—ultrasound signal is generated via impedance mismatch of the silica, optical imaging is enabled by an embedded fluorophore, and T1-weighted imaging is possible via chelated gadolinium (Fig. 5) [27]. Stem cells could then be labeled with these materials for both instant imaging at the time of delivery via ultrasound and long-term follow-up with MRI.

Fig. 5 Direct imaging with nanoparticles. Ultrasound (**a**) and MRI (**b**) images were collected before injection of 500,000 human mesenchymal stem cells in a rodent model. After injection, the animals were imaged again with obvious increases in signal indicating the presence of the cells on ultrasound (**c**) and MRI (**d**). Reproduced with permission from Ref. [29]

Once labeled, the nanoparticles increased the ultrasound and MRI contrast of labeled human mesenchymal stem cells 700 % and 200 %, respectively. The authors investigated the behavior of the agent on cell metabolic activity, proliferation, or pluripotency, but did not find any significant change. Electron microscopy and ultrasound imaging suggest that the mechanism of action is in vivo aggregation of the 300 nm silica nanoparticles into larger silica frameworks that amplify the ultrasound backscatter. Detection limits in cardiac tissue were 250,000 cells via MRI and 70,000 via ultrasound with cell imaging possible in animal models for 13 days after implantation (Fig. 5). This ultrasound-guided cell delivery and multimodal optical/ultrasound/MRI intracardiac cell-tracking platform could improve cell therapy in the clinic by minimizing mis-delivery or implantation into fibrotic tissue. Moreover, these materials were compatible with both preclinical and clinical ultrasound frequencies.

More recently, this same group has extended this work and developed ultrasound contrast agents that can not only produce ultrasound signal, but can also deliver pro-survival agents to increase stem cell survival and then biodegrade after the delivery and imaging tasks are complete. This was performed largely by transitioning from solid nanoparticles to mesoporous silica nanoparticles (MSNs) [28]. The MSNs still have an impedance mismatch between tissue and the silica particles, but also offer a high surface area (~1000 m^2/g) suitable for sustained release of drug [29, 30]. MSNs offer sustained release of insulin-like growth factor (IGF) in close proximity to cells at high local concentrations. They also allow imaging through multimodal approaches, which include MRI, optical, and ultrasound. Therefore, this approach allows IGF to be delivered to the cell surface membrane where the IGF receptors are located—this stimulates cell growth in the hypoxic and necrotic region of therapy.

Mesenchymal stem cells labeled with these nanoparticles had detection limits near 9000 cells with no cytotoxicity at the 250 μg/mL concentration required for labeling. Degradation studies showed that the nanoparticles clear from cells in approximately 3 weeks. The presence of IGF increased cell survival up to 40 % ($P < 0.05$) versus unlabeled cells under in vitro serum-free culture conditions. The degradation time is important because MSNs have to be stable for imaging, but not so stable that they never clear from the body. One limitation of this approach is that it is not a true marker of cell viability. It continuously produces a signal whether the cell is alive or not. This problem could be counteracted by conducting further studies utilizing a reporter gene [31].

2.3   Ultrasound Tracking of Neural Progenitor Cells

Another method that can allow the utilization of ultrasound for cell tracking is by introducing microbubbles into neural progenitor cells (NPCs). Modified NPCs have previously been proposed as a way to treat genetic disorders or to target tumors, infarction, or inflammation due to their ability to disperse bioactive molecules [32–34]. In 2013, Wenjin Cui and coworkers reported that ultrasound microbubbles could be used as a means to track NPCs in vivo [35].

The authors labeled the cells using positively charged perfluorocarbon micro-bubbles and the negatively charged cell membrane. Transfection efficiency and cell viability were both greater than 90 %. Detection limits down to a single cell at 7 MHz were possible. The microbubble-labeled NPCs were also more resistant to ultra-sound exposure showing that these were still detectable on day 7 versus the hours of in vivo stability for intravenously injected microbubbles. These results were due to the microbubbles associating themselves with the cell surfaces and being internal-ized. Yet the internalized microbubbles could still behave nonlinearly in ultrasound, produce harmonic signals, and be destroyed but at a higher pressure than free micro-bubbles. The ability to detect a single cell using microbubble-labeled cells and ultra-sound is advantageous when compared to current proposed in vivo cell tracking techniques (PET and bioluminescence), which usually require thousands of cells.

One limitation of this study was that there might have been a loss of signal in vivo due to possible cell migration out of the liver. The team carried out tests to monitor the accumulation after intravenous injection in the livers of mice. Eight mice were injected with the microbubble-labeled NPCs. Four were injected with the free microbubbles. The microbubble-labeled NPCs were still visible at day 5, but the free microbubbles were gone by 8 h. The NPCs may have leaked to other areas leading to the decay of signal. This cannot be completely confirmed because the authors only studied the liver. Some microbubbles may have been released upon cell death. Nevertheless, this long lifetime is very useful for both real-time imaging of implantation and longitudinal stem cell tracking.

2.4   Indirect Imaging with Ultrasound

All of the above examples use direct imaging—that is, a nanoparticle or microbub-ble directly bound to the stem cell. However, indirect imaging offers many advan-tages including true representation of cell viability. One exciting report of an ultrasound reporter genes [36] used biogenic gas vesicles. These vesicles help bac-teria maintain their proper depth in water for photosynthesis. Researchers isolated the genes responsible for these vesicles and loaded them into cells. These materials are protein-shelled compartments with typical widths of 45–250 nm and lengths of 100–600 nm. They exclude water but are gas permeable.

There are very few applications of indirect ultrasound imaging in regenerative medicine. One report in 2009 by Kuliszewski and coworkers described a method to utilize ultrasound for indirect cell imaging in vivo (Fig. 6) [37]. Here, cells were programmed to make a specific cell surface protein H-2Kk. Then microbubbles targeted to this protein were injected intravenously. Because the cell surface protein was only on the stem cells, specific signal could be obtained. The stem cells used in this application were endothelial progenitor cells (EPCs), and Kuliszewski hypothesized that the targeted microbubbles would bind to cells in vivo. The micro-bubbles were conjugated with a biotinylated anti-H-2Kk antibody and then injected for in vivo EPC imaging. The EPCs were implanted into rats and for ultrasound

Fig. 6 Indirect imaging. (**a**) H-2Kk-transfected EPCs (*left* implant) and EPC cells (*right* implant) and treated with control, non-targeted bubbles do not show accumulation. (**b**) However, when H-2Kk-targeted bubbles are injected, the H-2kK-expressing cells specifically bind the bubbles (left implant; panel **b**). There is only background signal in the other cell types. This is further quantified in panel **c**. * and # indicate $P < 0.005$. Reproduced with permission from Ref. [39]

imaging. After 1 week, imaging showed perfusion within the cell areas and a strong signal for microbubbles with H-2Kk in the H-2Kk-transfected EPC-supplemented plug (Fig. 6). Negative controls including non-targeted microbubbles and cells not expressing H-2Kk were negative. This finding shows that microbubbles targeted to an engineered cell-surface marker on EPCs can be tracked with ultrasound.

Limitations include the use of electroporation for EPC transduction. The H-2Kk gene expression was also transient. The reduction in EPC transduction was due to active cell division during culture. Another limitation is that the in vivo model of the matrigel angiogenesis may not accurately recapitulate clinical cell therapy due to inefficient cell delivery methods and a gradual decrease in the number of engrafted EPCs over time. In addition, the use of microbubbles is limited to vascular targets.

3   Photoacoustic Imaging of Stem Cell Therapy

Another useful way to track cells in vivo is to utilize photoacoustic imaging using an exogenous contrast agent. These agents produce ultrasound waves through a pressure difference caused by rapid heating from a nanosecond pulse of light on the

sample. This technique complements traditional ultrasound and increases contrast. It is noninvasive and quantitative, and has quick scan times. Multiple groups have used photoacoustic imaging for cell tracking [38–40] and cancer stem cells [41, 42].

In one example, Jokerst et al. reported the use of silica-coated GNRs (SiGNRs) as a photoacoustic contrast agent and combined it with ultrasound backscatter mode imaging (Fig. 7) [38]. Stem cells were labeled with the SiGNRs, and imaged in mice, and the effect of the SiGNRS on cell viability, differentiation, and cytokine expression was measured. The silica coat played two important roles—the photoacoustic signal of the GNRs was strengthened approximately fourfold confirming Emelianov's earlier report [43]. This signal increase remained stable for at least 60 days after coating. The second important role of silica was to increase accumulation of the contrast agent in the cell more the bare gold nanorods. Transmission electron microcopy images clearly illustrate SiGNRs (Fig. 7a) inside of stem cells (Fig. 7b). Photoacoustic imaging with B-mode ultrasound imaging provides an image with clearly defined anatomic features with photoacoustic data that contain cell-specific

Fig. 7 Photoacoustic imaging. (**a**) Silica-coated gold nanorods are photoacoustic contrast agents that can be loaded into stem cells (**b**). (**c**) Ultrasound imaging provides details on anatomy including muscle, bone, and skin. Photoacoustic ultrasound (**d**) offers increased contrast unique to the stem cells (*dashed yellow box*). Reproduced with permission from Ref. [40]

content (Fig. 7c, d). Limitations include optical scatter due to the nature of tissue as well as inaccuracies with reconstructions. This could be solved by using a photo-acoustic catheter or endoscope for deep-tissue implantation.

In another application, Nam and coworkers imaged stem cells labeled with gold nanotracers [40]. The labeled stem cells were mixed into a fibrin gel and injected into the lateral gastrocnemius muscle of a rat 5 mm beneath the skin. Ultrasound/ photoacoustic images were taken and clearly show the location of the nanotracer signal of the cells indicating high sensitivity. In vivo detection limits were 4.5×10^9 nanoparticles/mL. This facilitates high-sensitivity imaging.

4   Perspectives and Conclusions

Ultrasound imaging offers many advantages to the stem cell imager. It has high temporal and spatial resolution and is also very affordable. Portable units can be purchased for below $10,000. This makes it applicable both to sophisticated research hospitals and rural or private practice clinics. As the field of regenerative medicine continues to expand, the number of people using ultrasound for cell imaging will likely increase.

We will also likely see other applications in different organ systems. Ultrasound is routinely used in many abdominal applications including imaging of the liver, spleen, and bowels. Regenerative medicine applications are likely in these areas, and ultrasound may be a very useful tool to investigators in the field. Ultrasound is also used to study joints including the knees. There are clinical trials under way using stem cells to regenerate cartilage to prevent joint pain. Ultrasound is ideally suited to understand the location and distribution of stem cells in the joints.

The community will also continue to see multimodal applications. As shown above, ultrasound and MRI are very complementary techniques in terms of tissue penetration and temporal resolution. Other groups have shown ultrasound combined with Raman imaging, which is a special optical technique with exquisite sensitivity and spectral character, but very slow temporal resolution. Thus, these two techniques can be used in tandem to minimize the relative disadvantages of each technique. Finally, researchers will continue to study ways to increase contrast in ultrasound. While photoacoustics is promising, it remains a body surface-weighted technique. Thus, magneto-acoustic or radio-frequency acoustic techniques will hopefully improve for use in humans. The interested reader is encouraged to learn more using these helpful texts [11, 44, 45].

References

1. Daar AS, Greenwood HL. A proposed definition of regenerative medicine. J Tissue Eng Regen Med. 2007;1(3):179–84.
2. Mason C, Dunnill P. A brief definition of regenerative medicine. Regen Med. 2008;3(1):1–5.

3. Lane SW, Williams DA, Watt FM. Modulating the stem cell niche for tissue regeneration. Nat Biotechnol. 2014.
4. George JC. Stem cell therapy in acute myocardial infarction: a review of clinical trials. Transl Res. 2010;155(1):10–9.
5. Bolli R, Chugh AR, D'Amario D, Loughran JH, Stoddard MF, Ikram S, et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet. 2011;378(9806):1847–57.
6. Gilbert PM, Havenstrite KL, Magnusson KE, Sacco A, Leonardi NA, Kraft P, et al. Substrate elasticity regulates skeletal muscle stem cell self-renewal in culture. Science. 2010;329(5995): 1078–81.
7. Tedesco FS, Dellavalle A, Diaz-Manera J, Messina G, Cossu G. Repairing skeletal muscle: regenerative potential of skeletal muscle stem cells. J Clin Invest. 2010;120(1):11.
8. Wakitani S, Okabe T, Horibe S, Mitsuoka T, Saito M, Koyama T, et al. Safety of autologous bone marrow-derived mesenchymal stem cell transplantation for cartilage repair in 41 patients with 45 joints followed for up to 11 years and 5 months. J Tissue Eng Regen Med. 2011;5(2):146–50.
9. Orlando G, Baptista P, Birchall M, De Coppi P, Farney A, Guimaraes-Souza NK, et al. Regenerative medicine as applied to solid organ transplantation: current status and future challenges. Transpl Int. 2011;24(3):223–32.
10. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414(6859):105–11.
11. Kircher MF, Gambhir SS, Grimm J. Noninvasive cell-tracking methods. Nat Rev Clin Pract. 2011;8(11):677–88.
12. Atala A, Allickson J. Translational regenerative medicine. Burlington: Elsevier Science; 2014. ScienceDirect. Restricted to UC campuses http://uclibs.org/PID/267828
13. Bulte JW, Kraitchman DL. Iron oxide MR contrast agents for molecular and cellular imaging. NMR Biomed. 2004;17(7):484–99.
14. Khurana A, Chapelin F, Beck G, Lenkov OD, Donig J, Nejadnik H, et al. Iron administration before stem cell harvest enables mr imaging tracking after transplantation. Radiology. 2013;269(1):186–97.
15. Fu Y, Kraitchman DL. Stem cell labeling for noninvasive delivery and tracking in cardiovascular regenerative therapy. Expert Rev Cardiovasc Ther. 2010;8(8):1149–60.
16. Bunce S, Moore A, Hough A. M-mode ultrasound: a reliable measure of transversus abdominis thickness? Clin Biomech. 2002;17(4):315–7.
17. Adler DD, Carson PL, Rubin JM, Quinn-Reid D. Doppler ultrasound color flow imaging in the study of breast cancer: preliminary findings. Ultrasound Med Biol. 1990;16(6):553–9.
18. Paulus WJ, Tschöpe C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 2007.
19. Nguyen PK, Lan F, Wang Y, Wu JC. Imaging: guiding the clinical translation of cardiac stem cell therapy. Circ Res. 2011;109(8):962–79.
20. Rodriguez-Porcel M, Gheysens O, Chen IY, Wu JC, Gambhir SS. Image-guided cardiac cell delivery using high-resolution small-animal ultrasound. Mol Ther. 2005;12(6):1142–7.
21. Vunjak-Novakovic G, Lui KO, Tandon N, Chien KR. Bioengineering heart muscle: a paradigm for regenerative medicine. Annu Rev Biomed Eng. 2011;13:245–67.
22. de Vries IJ, Lesterhuis WJ, Barentsz JO, Verdijk P, van Krieken JH, Boerman OC, et al. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol. 2005;23(11):1407–13.
23. Bara C, Ghodsizad A, Niehaus M, Makoui M, Piechaczek C, Martin U, et al. In vivo echocardiographic imaging of transplanted human adult stem cells in the myocardium labeled with clinically applicable CliniMACS nanoparticles. J Am Soc Echocardiogr. 2006;19(5):563–8.
24. Kompa AR, Summers RJ. Lidocaine and surgical modification reduces mortality in a rat model of cardiac failure induced by coronary artery ligation. J Pharmacol Toxicol Methods. 2000;43(3):199–203.

25. Casciaro S, Conversano F, Ragusa A, Ada Malvindi M, Franchini R, Greco A, et al. Optimal enhancement configuration of silica nanoparticles for ultrasound imaging and automatic detection at conventional diagnostic frequencies. Invest Radiol. 45(11):715–23.
26. Martinez HP, Kono Y, Blair SL, Sandoval S, Wang-Rodriguez J, Mattrey RF, et al. Hard shell gas-filled contrast enhancement particles for colour Doppler ultrasound imaging of tumors. Med Chem Commun. 2010;1(4):266–70.
27. Jokerst JV, Khademi C, Gambhir SS. Intracellular aggregation of multimodal silica nanoparticles for ultrasound-guided stem cell implantation. Sci Transl Med. 2013;5(177):177ra35.
28. Kempen PJ, Greasley S, Parker KA, Campbell JL, Chang H-Y, Jones JR, et al. Theranostic mesoporous silica nanoparticles biodegrade after pro-survival drug delivery and ultrasound/ magnetic resonance imaging of stem cells. Theranostics. 2015;5(6):631.
29. Slowing II, Trewyn BG, Giri S, Lin VSY. Mesoporous silica nanoparticles for drug delivery and biosensing applications. Adv Funct Mater. 2007;17(8):1225–36.
30. Liu J, Stace-Naughton A, Jiang X, Brinker CJ. Porous nanoparticle supported lipid bilayers (protocells) as delivery vehicles. J Am Chem Soc. 2009;131(4):1354–5.
31. Yaghoubi SS, Jensen MC, Satyamurthy N, Budhiraja S, Paik D, Czernin J, et al. Noninvasive detection of therapeutic cytolytic T cells with 18F–FHBG PET in a patient with glioma. Nat Clin Pract Oncol. 2008;6(1):53–8.
32. Brown AB, Yang W, Schmidt NO, Carroll R, Leishear KK, Rainov NG, et al. Intravascular delivery of neural stem cell lines to target intracranial and extracranial tumors of neural and non-neural origin. Hum Gene Ther. 2003;14(18):1777–85.
33. Silva GA, Czeisler C, Niece KL, Beniash E, Harrington DA, Kessler JA, et al. Selective differentiation of neural progenitor cells by high-epitope density nanofibers. Science. 2004; 303(5662):1352–5.
34. Wang L, Martin DR, Baker HJ, Zinn KR, Kappes JC, Ding H, et al. Neural progenitor cell transplantation and imaging in a large animal model. Neurosci Res. 2007;59(3):327–40.
35. Cui W, Tavri S, Benchimol MJ, Itani M, Olson ES, Zhang H, et al. Neural progenitor cells labeling with microbubble contrast agent for ultrasound imaging in vivo. Biomaterials. 2013;34(21):4926–35.
36. Shapiro MG, Goodwill PW, Neogy A, Yin M, Foster FS, Schaffer DV, et al. Biogenic gas nanostructures as ultrasonic molecular reporters. Nat Nanotechnol. 2014;9(4):311–6.
37. Kuliszewski MA, Fujii H, Liao C, Smith AH, Xie A, Lindner JR, et al. Molecular imaging of endothelial progenitor cell engraftment using contrast-enhanced ultrasound and targeted microbubbles. Cardiovasc Res. 2009;83(4):653.
38. Jokerst JV, Thangaraj M, Kempen PJ, Sinclair R, Gambhir SS. Photoacoustic imaging of mesenchymal stem cells in living mice via silica-coated gold nanorods. ACS Nano. 2012;6(7):5920–30.
39. Wang C, Ma X, Ye S, Cheng L, Yang K, Guo L, et al. Protamine functionalized single-walled carbon nanotubes for stem cell labeling and in vivo raman/magnetic resonance/photoacoustic triple-modal imaging. Adv Funct Mater. 2012;22(11):2363–75.
40. Nam SY, Ricles LM, Suggs LJ, Emelianov SY. In vivo ultrasound and photoacoustic monitoring of mesenchymal stem cells labeled with gold nanotracers. PLoS One. 2012;7(5), e37267.
41. Galanzha EI, Kim J-W, Zharov VP. Nanotechnology-based molecular photoacoustic and photothermal flow cytometry platform for in vivo detection and killing of circulating cancer stem cells. J Biophotonics. 2009;2(12):725.
42. Hu X, Wei CW, Xia J, Pelivanov I, O'Donnell M, Gao X. Trapping and photoacoustic detection of CTCs at the single cell per milliliter level with magneto-optical coupled nanoparticles. Small. 2013;9(12):2046–52.
43. Chen YS, Frey W, Kim S, Kruizinga P, Homan K, Emelianov S. Silica-coated gold nanorods as photoacoustic signal nanoamplifiers. Nano Lett. 2011;11(2):348–54.
44. Atala A, Allickson J. Translational regenerative medicine. London, UK: Academic Press; 2014.
45. Wang J, Jokerst JV. Stem cell imaging: tools to improve cell delivery and viability. Stem Cell Int. 2016. In press.